Update on ArtemiC phase II trial on COVID-19 patients
Filed with ASX · · 4 pages · English
Story so far
Earlier from Argent Biopharma
- Mxc welcomes new FCA guidance for cannabis sector in the UK
- Mxc well positioned for tga down-schedule of cbd products
- $15M finance facility to fund revenue growth for key markets
- Appendix 4E and Preliminary Unaudited Financial Report
- JV to be established for registration of ArtemiC in Russia
Later from Argent Biopharma
- MGC pharma launches CannEpil app
- First high THC products shipped direct to Brazil patients
- ArtemiC histology on rats confirm no pathological impact
- Mgc pharma delivers record consecutive weekly sales growth
- September Quarterly Activity and Cashflow Report
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma